Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
SAGE Therapeutics (SAGE)
NASDAQ:SAGE
Holding SAGE?
Track your performance easily
SAGE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.84 - $28.26
Previous Close$8.01
Volume661.81K
Average Volume (3M)656.41K
Market Cap
$489.01M
Enterprise Value-$156.37M
Total Cash (Recent Filing)$646.79M
Total Debt (Recent Filing)$1.41M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Oct 29, 2024EPS Estimate
-$1.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.41
Shares Outstanding61,050,418
10 Day Avg. Volume559,275
30 Day Avg. Volume656,410
Standard Deviation0.16
R-Squared0.08
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.78
Price to Sales (P/S)5.03
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-9.13
Enterprise Value/Gross Profit-1.81
Enterprise Value/Ebitda0.26
Forecast
1Y Price Target
$10.92Price Target Upside36.33% Upside
Rating ConsensusHold
Number of Analyst Covering17
SAGE Therapeutics News
Bulls Say, Bears Say
Bulls Say
Market ExpansionCommercial coverage of Zurzuvae increased significantly, with the majority of states having made coverage decisions and additional states expected to complete reviews, easing potential bottlenecks in driving adoption.
Product LaunchZurzuvae shows progress with OB/GYNs leading the script writing, which bodes well for future growth.
Sales PerformanceZurzuvae sales were modestly above consensus, and there is encouragement from the strong prescription growth and significant commercial and Medicaid coverage expansion.
Bears Say
Pipeline FailuresThe failure comes after negative readouts for dalza’ in Parkinson’s and SAGE-324 in essential tremor, raising questions about the future of the pipeline.
Sales PerformanceZurzuvae sales were below forecast due to wholesaler destocking and free drugs, with potential for more destocking.
Workforce ReductionA reduction of approximately 33% of the total workforce and 55% of the R&D workforce will occur, including senior leadership changes.
---
Ownership Overview
1.56% Insiders
23.92% Mutual Funds
0.86% Other Institutional Investors
57.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SAGE FAQ
What was SAGE Therapeutics’s price range in the past 12 months?
SAGE Therapeutics lowest stock price was $5.84 and its highest was $28.26 in the past 12 months.
What is SAGE Therapeutics’s market cap?
Currently, no data Available
When is SAGE Therapeutics’s upcoming earnings report date?
SAGE Therapeutics’s upcoming earnings report date is Oct 29, 2024 which is 6 days ago.
How were SAGE Therapeutics’s earnings last quarter?
SAGE Therapeutics released its earnings results on Jul 31, 2024. The company reported -$1.7 earnings per share for the quarter, missing the consensus estimate of -$1.641 by -$0.059.
Is SAGE Therapeutics overvalued?
According to Wall Street analysts SAGE Therapeutics’s price is currently Undervalued.
Does SAGE Therapeutics pay dividends?
SAGE Therapeutics does not currently pay dividends.
What is SAGE Therapeutics’s EPS estimate?
SAGE Therapeutics’s EPS estimate is -$1.54.
How many shares outstanding does SAGE Therapeutics have?
SAGE Therapeutics has 61,050,420 shares outstanding.
What happened to SAGE Therapeutics’s price movement after its last earnings report?
SAGE Therapeutics reported an EPS of -$1.7 in its last earnings report, missing expectations of -$1.641. Following the earnings report the stock price went up 1.389%.
Which hedge fund is a major shareholder of SAGE Therapeutics?
Among the largest hedge funds holding SAGE Therapeutics’s share is Fisher Asset Management LLC. It holds SAGE Therapeutics’s shares valued at 5M.
---
SAGE Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.92 (36.33% Upside)
$10.92 (36.33% Upside)
Hedge Fund Trend
Decreased
By 618.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.22%
12-Months-Change
Fundamentals
Return on Equity
-55.28%
Trailing 12-Months
Asset Growth
-35.59%
Trailing 12-Months
Company Description
SAGE Therapeutics
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
---
SAGE Company Deck
---
SAGE Earnings Call
Q2 2024
0:00 / 0:00
---
SAGE Stock 12 Month Forecast
Average Price Target
$10.92
▲(36.33% Upside)
Technical Analysis
Best Analysts Covering SAGE
1 Year
1 Year Success Rate
9/14 ratings generated profit
1 Year Average Return
+38.81%
downgraded a sell rating last month
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +38.81% per trade.
---